Chemoenzymatic studies of aminoglycoside-resistance enzymes towards new drugs

新药氨基糖苷类耐药酶的化学酶学研究

• 批准号: 8505365
• 负责人: Sylvie Garneau-Tsodikova
• 金额: $ 40.36万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8505365
• 关键词: Acetylation; Acetyltransferase; Acquired Immunodeficiency Syndrome; Acute; Acyl Coenzyme A; Affinity; Amines; Aminoglycoside Antibiotics; Aminoglycoside resistance; Aminoglycosides; Anti-Bacterial Agents; Antibiotics; Bacillus anthracis; Bacteria; Bacterial Infections; Biochemical; Biological; Chemicals; Chemistry; Clinic; Clinical; Coenzyme A; Collaborations; Complement; Complex; Cystic Fibrosis; Development; Disease; Drug Targeting; Drug resistance; Drug resistance in tuberculosis; Enterococcus faecalis; Enzymes; Extreme drug resistant tuberculosis; Family; Health; Homologous Gene; Human; In Vitro; Kanamycin A; Kinetics; Klebsiella pneumonia bacterium; Lead; Libraries; Malignant Neoplasms; Methodology; Methods; Michigan; Modification; Multi-Drug Resistance; Mycobacterium tuberculosis; N acylation; One-Step dentin bonding system; Parents; Pathway interactions; Pharmaceutical Preparations; Positioning Attribute; Proteins; Public Health; Research; Resistance; Resistance development; Ribosomes; Series; Solutions; Structure; Testing; Therapeutic; Time; Toxic effect; Tuberculosis; Universities; Work; aminoglycoside acetyltransferase; analog; antimicrobial drug; bacterial resistance; chemical synthesis; combat; cost; drug resistant bacteria; fascinate; improved; inhibitor/antagonist; innovation; insight; novel; novel therapeutics; pathogen; pathogenic bacteria; prevent; resistance mechanism; resistant strain; therapeutic protein

DESCRIPTION (provided by applicant): Aminoglycosides are broad-spectrum antibiotics used for treatment of serious bacterial infections, including the deadly tuberculosis and those accompanying AIDS, cystic fibrosis, and cancer. The emergence of pathogens resistant to these drugs represents a major threat to public health and underscores the need for new antimicrobial agents. In Aim 1, we propose to utilize aminoglycoside-modifying enzymes of the aminoglycoside acetyltransferase (AAC) family in conjunction with a newly developed 6'-N-acylation protecting group-free chemical methodology (i) to generate in vitro libraries of new and more potent N-acylated aminoglycoside antibiotics, and (ii) to develop aminoglycoside probes that will serve as baits for identification of novel therapeutic protein targets/pathways for these antibiotics. Our chemoenzymatic and chemical strategies offer an effective solution to the following problems: (i) there are no existing general synthetic methodologies for the creation of N-acylated aminoglycosides, and (ii) there are no efficient methods to chemically modify specific amine groups on an aminoglycoside that contains a series of chemically identical amines. A few existing examples that use solely chemical syntheses are too demanding on research time and cost and are limited to very specific cases. In Aim 2, we propose biochemical and structural studies of the mechanism of action and inhibition of a major determinant of aminoglycoside resistance in extensively drug-resistant strains of M. tuberculosis (XDR-TB). We expect this work to (i) advance the basic understanding of AG resistance of a variety of pathogenic bacteria, including M. tuberculosis, and (ii) provide a potential solution to overcome the aminoglycoside resistance problem in majority of XDR- TB. Relevance to public health: We expect that this work will contribute to the development of novel antibiotics with a potential to combat existing and newly emerging drug-resistant bacteria.

说明(申请人提供)：氨基糖苷类抗生素是一种广谱抗生素，用于治疗严重的细菌感染，包括致命的结核病和伴随艾滋病、囊性纤维化和癌症的细菌感染。对这些药物具有抗药性的病原体的出现是对公共健康的重大威胁，并突出表明需要新的抗菌剂。在目标1中，我们建议利用氨基糖苷乙酰转移酶(AAC)家族的氨基糖苷类修饰酶，结合新开发的6‘-N-酰化保护基团的化学方法学(I)建立新的和更有效的N-酰化氨基糖苷类抗生素的体外文库，以及(Ii)开发氨基糖苷类探针，作为诱饵来鉴定这些抗生素的新的治疗蛋白质靶点/途径。我们的化学酶和化学策略为以下问题提供了有效的解决方案：(I)目前还没有通用的合成方法来创建N-酰化氨基糖苷类化合物，以及(Ii)没有有效的方法来化学修饰含有一系列化学相同胺的氨基糖苷类化合物上的特定胺基。现有的几个单独使用化学合成的例子对研究时间和成本要求太高，而且仅限于非常具体的情况。在目标2中，我们建议对广泛耐药结核分枝杆菌(XDR-TB)氨基糖苷耐药的一个主要决定因素的作用机制和抑制机制进行生化和结构研究。我们希望这项工作(I)促进对包括结核分枝杆菌在内的各种病原菌对AG耐药性的基本了解，并(Ii)提供一种潜在的解决方案，以克服大多数XDR-TB的氨基糖苷类耐药性问题。与公众健康相关：我们预计这项工作将有助于开发新的抗生素，有可能对抗现有的和新出现的耐药细菌。